Submitted by moderatorj on Mon, 06/25/2012 - 23:24
Helix BioPharma Corp. Announces Selection of CEO; Plans to Voluntarily Delist From NYSE MKT
Yahoo/MarketWire
Submitted by moderatorj on Fri, 05/18/2012 - 18:51
Helix BioPharma receives approval to conduct Phase III clinical trial
Yahoo/TheFlyOnTheWall
Submitted by moderatorj on Thu, 04/05/2012 - 18:51
Helix BioPharma Corp. Reconstituted Board of Directors Provides Update to Shareholders
Yahoo/MarketWire
Submitted by moderatorj on Wed, 03/14/2012 - 22:06
Helix BioPharma Corp. Announces Agreed Changes to the Board of Directors and Settlement With Concerned Shareholders
Yahoo/MarketWire
Submitted by moderatorj on Mon, 01/23/2012 - 21:24
Helix BioPharma Corp. Announces That Institutional Shareholder Services Recommends Shareholders Vote for Management's Director Nominees
Yahoo/MarketWire
Submitted by moderatorj on Fri, 12/23/2011 - 18:31
Helix BioPharma Corp. Files Clinical Trial Applications for Its Planned European Phase III Efficacy Trial of Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
Submitted by moderatorj on Wed, 11/16/2011 - 23:38
Helix BioPharma Corp. Announces Appointment of Special Committee
Yahoo/MarketWire
Submitted by moderatorj on Fri, 11/11/2011 - 18:14
Clinical Hold Removed for Helix BioPharma Corp.'s Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application
Yahoo/MarketWire
Submitted by moderatorj on Mon, 10/31/2011 - 22:16
Helix BioPharma Corp. Announces Fiscal 2011 Results
Yahoo/MarketWire
Submitted by moderatorj on Thu, 10/20/2011 - 22:55
Helix BioPharma Corp. Terminates Agreement With ACM Alpha Consulting Management Est.
Yahoo/MarketWire